
Dyne Therapeutics (DYN) Stock Forecast & Price Target
Dyne Therapeutics (DYN) Analyst Ratings
Bulls say
Dyne Therapeutics is a clinical-stage neuromuscular disease company that utilizes its proprietary FORCE platform to develop targeted therapeutics for genetically driven neuromuscular diseases. Their lead programs have shown promising clinical data, with potential for differentiation in the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. Despite some residual risks, as with any biotechnology company, we believe Dyne has strong potential for success and could become a leader in the rare genetic muscle disease space.
Bears say
Dyne Therapeutics is currently facing several fundamental challenges that may impact the success and valuation of its FORCE platform, including the potential for safety issues and a residual clinical risk in its programs. Additionally, the recent setback from NVS in a similar therapy casts doubt on DYN's ability to meet its primary endpoint in upcoming trials. These factors, along with a potential lack of statistically significant results and a reliance on biopsies and unadjusted data, lead to our negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction
Start investing in Dyne Therapeutics (DYN)
Order type
Buy in
Order amount
Est. shares
0 shares